Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.


Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... (more)

Stock Performance

NASDAQ: ACHN

| Last Trade | 3.00 |
| Trade Time: | 4:00 PM ET Feb 21, 2018 |
| Change: | -0.01 (-0.332%) |
| Day Range | 2.97 - 3.12 |
| 52-Week Range | 2.58 - 5.66 |
| Volume | 1,836,189 |

Press Releases [View all]

Feb 9, 2018
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Dec 20, 2017
Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

Dec 18, 2017
Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study

Nov 15, 2017
Achillion Announces Pricing of Secondary Offering Of Common Stock

Nov 14, 2017
Achillion Announces Proposed Secondary Offering of Common Stock

Upcoming Events [View all]

Feb 22, 2018 8:30 AM ET
Achillion Q4 & Year End 2017 Financial Results

Financial Disclosures [View all]

Third Quarter Financial Results

Feb 23, 2017
Annual Report (10-K)

Apr 17, 2017
Proxy Statement (DEF 14A)

Nov 1, 2017
Quarterly Report (10-Q)

Aug 8, 2017
Quarterly Report (10-Q)

May 4, 2017
Quarterly Report (10-Q)